RSPH10B Inhibitors
RSPH10B inhibitors pertain to a class of chemical compounds that specifically interact with and inhibit the function of the protein known as Radial Spoke Head 10 Homolog B (RSPH10B). The RSPH10B protein is part of the radial spoke head complex in cilia and flagella, which are hair-like structures on the surface of eukaryotic cells that play a crucial role in cell motility and signal transduction. The structure of these inhibitors is designed to bind with RSPH10B, thereby affecting the normal functioning of cilia and flagella. These inhibitors are the result of targeted research and are characterized by their selectivity, as they aim to achieve a high affinity for RSPH10B while minimizing interaction with other proteins. Their design often encompasses a variety of molecular frameworks that can include small molecules, peptides, or other synthetic compounds, fashioned to engage with the active or regulatory sites of RSPH10B.
The development and characterization of RSPH10B inhibitors are grounded in the detailed understanding of the protein's structure, function, and the biological pathways it influences. Advances in structural biology and computational chemistry have facilitated the creation of these inhibitors by illuminating the precise molecular interactions and conformations that are critical for RSPH10B activity. Research on these inhibitors involves a multifaceted approach, including the synthesis of potential inhibitory molecules followed by in vitro and in vivo assays to evaluate their efficacy in affecting RSPH10B activity. The biochemical studies typically involve the assessment of binding kinetics, the stability of the inhibitor-protein complex, and the molecular dynamics simulations to predict and analyze the behavior of these complexes. Furthermore, understanding the structural motifs and chemical properties that underlie the function of RSPH10B is imperative for the rational design of these inhibitors, ensuring specificity and efficacy in their interaction with the protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 disrupts PI3K-dependent signaling pathways. RSPH10B is thought to be involved in ciliary function and structure. By inhibiting PI3K, LY294002 can indirectly affect ciliary processes, potentially reducing RSPH10B activity. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Spautin-1 is known for promoting the degradation of class III PI3K complexes through inhibiting ubiquitin-specific peptidases. Since RSPH10B is associated with ciliary function, the disruption of PI3K signaling can indirectly lead to impairment of ciliary processes, thereby inhibiting RSPH10B's function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A selective inhibitor of ROCK kinases, Y-27632 impedes cytoskeletal organization by affecting actin filament assembly. Given that RSPH10B is implicated in the structural integrity of cilia, altering actin dynamics can potentially disrupt ciliary function, indirectly inhibiting RSPH10B. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, which is involved in inflammatory responses and cell differentiation. Since RSPH10B plays a role in ciliary structure, the inhibition of p38 MAPK may indirectly affect ciliary assembly or function, thereby inhibiting RSPH10B. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK1/2, U0126 prevents the activation of the MAPK/ERK pathway. The MAPK/ERK pathway is involved in a broad range of cellular processes, including cell growth and differentiation. By inhibiting this pathway, U0126 could indirectly affect ciliary functions linked to RSPH10B. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
A specific inhibitor of the vacuolar-type H+-ATPase, Bafilomycin A1 disrupts lysosomal acidification and autophagy. As RSPH10B is involved in ciliary function, the inhibition of autophagy can affect ciliary turnover and homeostasis, potentially leading to indirect inhibition of RSPH10B. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
By inhibiting actin polymerization, Cytochalasin D results in disruption of actin filaments. Given that RSPH10B is implicated in the ciliary structure, the destabilization of the actin cytoskeleton can lead to compromised ciliary architecture, indirectly affecting RSPH10B activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, leading to the blockade of the PI3K/Akt signaling pathway. Disruption of this pathway can lead to altered cellular processes, including those related to ciliary function, possibly resulting in the indirect inhibition of RSPH10B. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK), which in turn regulates myosin II activity in cells. Since myosin II is involved in maintaining the structure of cilia, inhibition by ML-7 could potentially alter ciliary function, thereby indirectly affecting RSPH10B. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
An antineoplastic antibiotic that crosslinks DNA, Mitomycin C can lead to the disruption of cellular replication and transcription processes. As RSPH10B is essential for proper ciliary function, such disruption can indirectly inhibit RSPH10B activity by affecting the expression of ciliary components. | ||||||